SUMMARY A dextran sulphate gel column removed anti-double-stranded DNA antibodies (antidsDNA) selectively, efficiently, and safely from the circulation of a patient with systemic lupus erythematosus (SLE). The mechanism of the removal is thought to be due to cross reactivity of anti-dsDNA with dextran sulphate, which has negatively charged units. Selective removal of antidsDNA is expected to contribute not only to the treatment but also to elucidation of the pathogenesis of SLE. Patient plasma (0.15 ml) was mixed with 0-1 ml dextran sulphate cellulose gel suspended in 1-0 ml TRIS-HCl buffer (0.15 M, pH 7-6) and incubated at room temperature for two hours with stirring. The gel was centrifuged, the supernatant obtained, and the remaining gel was packed into a column and washed thoroughly with TRIS-HCl buffer. Bound antibodies were then eluted with 2 M NaCl. The levels of anti-dsDNA and anti-single-stranded DNA (anti-ssDNA) 
are thought to play an essential part in the pathogenesis of this disease. Plasmapheresis, which removes these antibodies from the circulation, has been found to be an effective treatment for patients with active SLE.1 Plasmapheresis, in general, removes plasma non-selectively and often requires the use of plasma substitute, which is expensive and may potentially cause viral hepatitis or acquired immune deficiency syndrome. Selective removal of autoantibodies is therefore preferable.
Anti-dsDNA has been shown to cross react with repeating negatively charged molecules other than DNA.2 After confirming that anti-dsDNA also had a high affinity for dextran sulphate, which has repeating negatively charged units, we tried to remove anti-dsDNA from the circulation of a patient with SLE using a dextran sulphate sorbent column, which has been used widely as a specific adsorbent for low density lipoprotein in familial hyperlipidaemia.3
Accepted for publication 14 Patient plasma (0.15 ml) was mixed with 0-1 ml dextran sulphate cellulose gel suspended in 1-0 ml TRIS-HCl buffer (0.15 M, pH 7-6) and incubated at room temperature for two hours with stirring. The gel was centrifuged, the supernatant obtained, and the remaining gel was packed into a column and washed thoroughly with TRIS-HCl buffer. Bound antibodies were then eluted with 2 M NaCl. The levels of anti-dsDNA and anti-single-stranded DNA (anti-ssDNA) antibody in the supernatant and the eluate were measured.
Removal of anti-double-stranded DNA antibodies in SLE 857 peristaltic pump through a double lumen catheter inserted into the femoral vein of the patient. Plasma was separated at a speed of 25 ml/min and passed through the Liposorber with downward flow. The filtrate was infused into the patient with the blood cell-rich portion. Total extracorporeal circulation volume was about 400 ml. For anticoagulant, heparin was injected at an initial dose of 2000 units and then continuously infused at a rate of 800 units/h. Two litres of plasma were treated for each procedure. This procedure was performed three times a week.
MEASUREMENT
Before and after the immunoadsorption the total blood cells were counted and biochemical data were measured with a Technicon SMAC-C (Technicon Instruments Corp, Tarrytown, NY). Before and at times when each 0-5 litre of plasma had been treated, plasma was sampled before entering and after leaving the sorbent column. Biochemical data showed no abnormality. LE test and LE cell phenomenon were positive and a serological test for syphilis was negative. IgA was 2*56 g/l, IgG 14-63 g/l, IgM 0-42 g/l, C3 1*32 g/l, and C4 0-13 g/l. Fluorescence antinuclear antibody was positive at a titre of 1/2560 in a speckled pattern. IgG anti-dsDNA was 149 U/ml, IgM anti-dsDNA 19 U/ml, IgG anti-ssDNA 426 U/ml, and IgM antissDNA 200 U/ml, whereas the normal ranges of these anti-DNA are all less than 100 U/l. AntinRNP was positive at a titre of 1/320 by passive haemagglutination test. Anti-Sm antibody was negative. Urine analysis, electrocardiogram, chest x ray, electroencephalogram, spinal fluid analysis, and brain computed tomogram were all normal. He fulfilled the 1982 American Rheumatism Association revised criteria for SLE. The 30 mg of prednisolone that he was taking on admission was decreased to 25 mg at day 14. After a few days he 
Results
A study of the binding of anti-DNA with dextran sulphate gel in vitro showed that the titres of antidsDNA and anti-ssDNA in the supematant of the dextran sulphate gel were 22-3% and 34.2% that of the original plasma respectively, whereas those of the eluate were 71-0% and 63-5% respectively. Figure 1 Removal of anti-double-stranded DNA antibodies in SLE 859 where Cf and Ci are the final and initial concentrations respectively). The recovery rate of IgG antidsDNA was 0.596 (SD 0-099) and recovery rates of IgM anti-dsDNA, IgG anti-ssDNA, IgM antissDNA were almost the same as that of IgG antidsDNA (Table 1) . One session of immunoadsorption was able to reduce anti-dsDNA and antissDNA by about 40% of the original titre. Immune complexes decreased by as much as IgG antidsDNA. On the other hand, the recovery rate of anti-nRNP was 0*919 (0.064), indicating that anti-RNP was scarcely removed. Recovery rates of serum IgG, IgM, IgA, C3, and C4 were almost the same as that of anti-nRNP. Biochemical data, such as albumin, showed no change except for total cholesterol, triglyceride, low density lipoprotein, and very low density lipoprotein.
To evaluate the efficiency of the removal the value of the trapping coefficient f was calculated (f=1-Ca/Cb, where Ca and Cb are the concentrations of a plasma component after and before the immunoadsorbent column respectively). The trapping coefficient is 1.0 when adsorption is complete and gets smaller as the capacity for adsorption becomes lower. Figure 2 shows the titre of IgG antidsDNA of plasma before and after the immunoadsorbent column, and its trapping coefficient, at times when each 0-5 litre of plasma had been treated (a), and that of low density lipoprotein-cholesterol and its trapping coefficient (b). As the plasma treatment went on the titre of anti-dsDNA in plasma before the column continued to decrease as did that of low density lipoprotein. The trapping coefficient of anti-dsDNA was, however, reduced in proportion to the treated plasma volume, whereas that of low density lipoprotein was unchanged during the procedure.
Discussion
Seventy seven per cent of anti-dsDNA in the circulation could be removed selectively and safely by immunoadsorption using the Liposorber. AntidsDNA has been shown to bind not only to DNA, but also to hyaluronic acid, chondroitin sulphate, and heparan sulphate, which contain repeating negatively charged units.2 The mechanism of the removal by the Lipsorber is, therefore, thought to be by cross reactivity of anti-dsDNA with dextran sulphate, which also has repeating negatively charged units.
Immune complexes were removed as well as anti-dsDNA, though the mechanism is unknown. Anti-nRNP, on the other hand, was hardly removed. Anti-nRNP is thought to be an autoantibody with high specificity in comparison with anti-dsDNA or rheumatoid factor, and shows no cross reactivity. Plasma immunoglobulin was also hardly removed. As the recovery rate of IgG was 0-945 and the precipitation patterns of IgG in plasma before and after immunoadsorption in immunoelectrophoresis showed little difference (data not shown), the possibility that dextran sulphate removes the positively charged immunoglobulin non-selectively through electrostatic power seems unlikely.
Biochemical problems for general use. Difficulties include obtaining sufficient amount of material, preventing it from degenerating, and keeping it biologically active as well as the problem of sterilisation. Moreover, these materials may immunise the patients because of their heterogeneity and leak into the circulating blood to form immune complexes. In a study of the selective removal of low density lipoprotein3 dextran sulphate has been shown to have no antigenicity to humans as we also showed in this study.
The removal of anti-dsDNA, which is believed to play a major part in the pathogenesis of SLE, especially lupus nephritis, is expected to be an effective treatment for SLE, even though soluble mediators rather than anti-dsDNA may cause some of the clinical symptoms of SLE. In our patient clinical improvement was not clear after efficient removal of anti-dsDNA by immunoadsorption. This was partly because disease activity had already been suppressed by treatment with prednisolone, but also 860 Kinoshita, Aotsuka, Funahashi, Tani, Yokohari the anti-dsDNA removed by the Liposorber might not have played a major part in the clinical symptoms in this patient, who had not suffered from nephritis, and soluble mediators might have exerted a greater effect.
In conclusion, selective removal of anti-dsDNA would contribute not only to the treatment of patients with SLE, but also to elucidation of the precise role of this antibody in the pathogenesis of SLE. Plasma exchange or double membrane filtration plasmapheresis can also reduce anti-dsDNA. In such cases, however, the mechanisms of improvement are not clear because not only antibodies other than anti-dsDNA but also soluble mediators are non-selectively removed from the circulation. As the selectivity of the removal of substances improves the mechanisms of plasmapheresis may also become clear. Application of this immunoadsorption treatment to patients with SLE with greater clinical activity and a high titre of anti-dsDNA in a well controlled study will clarify the true efficacy of selective removal of anti-dsDNA, and we are now carrying out a multicentre trial to examine this aspect. Therefore, the findings reported herein should be viewed as a preliminary basis for future study.
